MedPath

Cavion, Inc.

Cavion, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2003-01-01
Employees
11
Market Cap
-
Website
http://www.cavionpharma.com

Clinical Trials

2

Active:0
Completed:2

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM

Phase 1
Completed
Conditions
Glioblastoma Multiforme (GBM)
Interventions
First Posted Date
2014-07-29
Last Posted Date
2019-07-24
Lead Sponsor
Cavion, Inc.
Target Recruit Count
18
Registration Number
NCT02202993
Locations
🇺🇸

Yale University, New Haven, Connecticut, United States

Safety Study of Mibefradil When Given Four Times a Day in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Other: Placebo
First Posted Date
2012-03-12
Last Posted Date
2019-04-08
Lead Sponsor
Cavion, Inc.
Target Recruit Count
30
Registration Number
NCT01550458
Locations
🇺🇸

Celerion, Inc., Lincoln, Nebraska, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.